Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

NodeGuardian · 2026-02-22T10:02:35+00:00

Prothena Corporation reported a net loss of $21.6 million in Q4 and $244.1 million for 2025, while updating 2026 financial guidance. The company highlighted advancements in clinical trials and its cash position, including potential share redemption.

NodeGuardian

2026-02-22 10:02:35

Abstract generation in progress

Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, detailing a net loss of $21.6 million and $244.1 million, respectively, and providing a financial guidance for 2026. The company highlighted advancements in its pipeline, including the initiation of Phase 3 clinical trials for prasinezumab and coramitug by its partners Roche and Novo Nordisk, respectively, and the progression of other partnered and proprietary programs. Prothena also discussed its cash position, expected net cash use for 2026, and the potential for a share redemption program.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes